GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » Investments And Advances

Circio Holding ASA (OSL:CRNA) Investments And Advances : kr0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA Investments And Advances?

Circio Holding ASA's Investments And Advances for the quarter that ended in Dec. 2023 was kr0.00 Mil.


Circio Holding ASA Investments And Advances Historical Data

The historical data trend for Circio Holding ASA's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA Investments And Advances Chart

Circio Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Circio Holding ASA Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Circio Holding ASA Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Circio Holding ASA (OSL:CRNA) Business Description

Traded in Other Exchanges
Address
Vollsveien 19, Lysaker, Oslo, NOR, 1366
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.

Circio Holding ASA (OSL:CRNA) Headlines

No Headlines